Search Within

James Joseph Harding

Formats
  1. Meeting Abstract (128)
  2. Journal Article (118)
  3. Review (7)
  4. Book Section (3)
  5. Miscellaneous (3)
  6. Editorial (1)
Groups
  1. Department of Medicine (260)
  2. Gastrointestinal Oncology Service (260)
  3. Solid Tumor Oncology Division (260)
  4. Center for Pancreatic Cancer Research (135)
  5. GSK Faculty (102)
  6. Epidemiology and Biostatistics (92)

More Groups

People
  1. Ghassan Abou-Alfa (135)
  2. Eileen O'Reilly (74)
  3. William Jarnagin (60)
  4. Michael Berger (40)
  5. Michael D'Angelica (40)
  6. Andrea Cercek Hanjis (39)

More People

Years
  1. 2025 (21)
  2. 2024 (32)
  3. 2023 (34)
  4. 2022 (21)
  5. 2021 (23)
  6. 2020 (20)

More Years

Publications
  1. Journal of Clinical Oncology (89)
  2. Annals of Oncology (20)
  3. Clinical Cancer Research (15)
  4. Annals of Surgical Oncology (13)
  5. JCO Precision Oncology (10)
  6. Cancer (9)

More Publications

Publishers
  1. American Society of Clinical Oncology (102)
  2. Oxford University Press (28)
  3. American Association for Cancer Research (23)
  4. Springer (21)
  5. Wiley Blackwell (14)
  6. Elsevier Science, Inc. (10)

More Publishers

Results (260)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Adjuvant modified FOLFIRINOX (mFFX) for resected pancreatic cancer (PDAC): Real world outcomes (RWO)
    Meeting Abstract

    Keane, F.; Balogun, F.; O'Connor, C.; Crowley, F.; Chan, A.; Cowzer, D.; Chou, J. F.; Park, W.; Varghese, A. M.; Yu, K. H.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Genetic heterogeneity of intrahepatic cholangiocarcinoma: Implications for outcome
    Meeting Abstract

    Song, Y.; Boerner, T.; Drill, E. N.; Shin, P.; Cercek, A.; Kemeny, N. E.; Abou-Alfa, G. K.; Iacobuzio-Donahue, C. A.; Schultz, N.; Walch, H. S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Concordance in oncogenic alterations between primary and recurrent/metastatic cholangiocarcinoma pairs using targeted next-generation sequencing
    Meeting Abstract

    McIntyre, S. M. H.; Preston, W.; Walch, H. S.; Sigel, C. S.; Sharib, J.; Chen, W.; Lidsky, M.; Kundra, R.; Cercek, A.; Harding, J. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Adjuvant chemotherapy for resected intrahepatic cholangiocarcinoma confers no survival advantage
    Meeting Abstract

    Sharib, J.; Liu, A.; McIntyre, S. M. H.; Rhodin, K. E.; Kemeny, N. E.; Cercek, A.; Harding, J. J.; Abou-Alfa, G. K.; Soares, K.; Wei, A. C. C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy
    Meeting Abstract

    Cowzer, D.; Huq, R.; Perry, M.; Keane, F.; Park, W.; El Dika, I. H.; Khalil, D.; Shia, J.; Sigel, C. S.; Bandlamudi, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase Ia/b first-in-human, open-label, multicenter study of BI 905711, a bispecific TRAILR2 agonist, in patients with advanced gastrointestinal cancers
    Meeting Abstract

    Harding, J. J.; Hofheinz, R. D.; Elez, E.; Kuboki, Y.; Rasco, D. W.; Cecchini, M.; Shen, L.; He, M.; Archuadze, S.; Chhaya, N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Rational development of combination therapies for biliary tract cancers
    Review

    Harding, J. J.; Khalil, D. N.; Fabris, L.; Abou-Alfa, G. K.
    Journal of Hepatology (2023)

    Fulltext@MSK | Save
  • Molecular characterization of gallbladder cancer
    Meeting Abstract

    Giraldo, N. A.; Mohanty, A.; Vanderbilt, C.; Brannon, R.; Benayed, R.; Vakiani, E.; Abou-Alfa, G.; Harding, J.; El Dika, I.; Schultz, N.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma
    Review

    de Castria, T. B.; Khalil, D. N.; Harding, J. J.; O'Reilly, E. M.; Abou-Alfa, G. K.
    Future Oncology (2022)

    Fulltext@MSK | Save
  • A phase Ia/b, open-label, multicentre study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers
    Meeting Abstract

    Harding, J. J.; Hofheinz, R. D.; Elez Fernandez, M. E.; Kuboki, Y.; Rasco, D.; Cecchini, M.; Shen, L.; Archuadze, S.; Geng, J.; Haderk, F.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save